

The Advantage of Choice

Regenerative Wound Solutions


TheraSKIN® | DermACELL Porous® | Matrion® | DermACELL AWM® | TheraGENESIS® | SonicONE®

LifeNet Health offers a complete portfolio of regenerative wound solutions designed to give healing every advantage. With more than 40 years of expertise, our commitment to a higher standard of quality is unwavering. Through a forward-focused design process and best-in-class quality controls, we've delivered more than 12 million allografts to patients worldwide.

LifeNet Health's Regenerative Wound Solutions products provide solutions for all wound types, head to toe.

TheraSKIN®

The Viable Advantage



TheraSkin is the only **all-human skin allograft with viable cells**, endogenous growth factors, and a native extracellular matrix that vascularizes to support the recipient building granulation tissue and facilitates epithelialization to help close wounds.²⁻⁴

- **111% greater closure rate** versus standard of care.¹
- Expansively covered: **276M covered lives** and counting
- Can be used over exposed bone, ligament, muscle, and tendon.

Proven to close in four or less applications¹

TheraSkin is available in **6 sizes** ranging from 3 to 116 cm²

DermACELL® Porous

The Porous Advantage



Dermacell Porous is a thin yet durable, naturally porous, **human ADM containing native growth factors**, extracellular matrix, and collagen ratios found in human dermis providing enhanced vascularization and cell infiltration.^{2,6-8}


- Non-sided graft for **easy handling and application**.
- Stored at room temperature and **ready to use**.⁹
- Can be used over exposed bone, ligament, muscle, and tendon.

Proven to close in four or less applications⁵

Dermacell Porous is available in **5 sizes** ranging from 3 to 42 cm²

Matrion®

The Powerful Advantage



Matrion is the first **human placental allograft** to utilize all three layers of the placental membrane including the trophoblast layer and is fully decellularized to not be pro-inflammatory.¹⁰⁻¹²

- **4x thicker** than traditional bilayer grafts.¹²
- Provides **50% more growth factors**.¹⁰
- Full-thickness durability promotes **superior handling**.


Matrion is available in **5 sizes** ranging from 3 to 64 cm²

GIVE HEALING EVERY ADVANTAGE™



DermACELL AWM®

The Durable Advantage



Dermacell AWM is a durable **human ADM containing growth factors** and an intact dermal structure that retains native extracellular matrix, and collagen ratios found in human dermis, promoting rapid cell infiltration, cell proliferation, and neo-vascularization.^{2,6,13}

- Drives an **81% decrease in amputations**.¹⁴
- Stored at room temperature and **ready to use**.
- Can be used over exposed bone, ligament, muscle, and tendon.

**Proven to close in
four or less applications⁵**

Dermacell AWM is available in
12 sizes ranging from 4 to 96 cm²

TheraGENESIS®

The Conformable Advantage



TheraGenesis is a **bilayer wound matrix xenograft** with a soft and flexible porcine atelocollagen-based layer and silicone protective layer that contains a reinforcing non-adhesive gauze (TRESTM). The biodegradable collagen matrix provides a scaffold for cellular invasion and capillary growth.

- Designed to **maximize conformability** and adherence to the wound bed.
- **Shorter treatment period** and time to secondary skin grafting (if required).¹⁵
- Does not inhibit cell proliferation.¹⁶

TheraGenesis is available in
7 sizes from 12 to 480 cm²

SonicONE®

The Debridement Advantage



SonicOne is an **ultrasonic debridement system** proven to remove devitalized tissue.¹⁷ The device effectively removes bacteria and biofilm, while preserving healthy tissue to improve wound healing outcomes.¹⁸⁻²⁰

- Reduces the wound bed bacterial load.²¹
- Preserve healthy tissue.¹⁹
- Reduce bleeding compared to sharp debridement.¹⁷

**as demonstrated in an abstract, n=20 patients*

SonicOne is available in
both the O.R. and Clinic settings



Contact your local LifeNet Health representative for more information.
LifeNetHealth.org/Wound

References

1. Armstrong DG, Galiano RD, Orgill DP, et al. Multi-centre prospective randomised controlled clinical trial to evaluate a bioactive split thickness skin allograft vs standard of care in the treatment of diabetic foot ulcers [published correction appears in Int Wound J. 2022 Aug;19(5):1276]. Int Wound J. 2022;19(4):932-944.
2. 68-20-047. Analysis of the Acellular Matrix, Growth Factors, and Cytokines Present in Oracell.
3. Landsman A, Rosines E, Houck A, Murchison A, Jones A, Qin X, Chen S, Landsman AR. Characterization of a Cryopreserved Split-Thickness Human Skin Allograft-TheraSkin. Adv Skin Wound Care. 2016 Sep;29(9):399-406. doi: 10.1097/01.ASW.0000489991.32684.9e. PMID: 27538107.
4. Towler MA, Rush EV, Richardson MK, Williams CL. Randomized, Prospective, Blinded-Enrollment, Head-To-Head Venous Leg Ulcer Healing Trial Comparing Living, Bioengineered Skin Graft Substitute (Apligraf) with Living, Cryopreserved, Human Skin Allograft (TheraSkin). Clin Podiatr Med Surg. 2018;35(3):357-365.
5. Cazzell S, Vayser D, Pham H, et al. A randomized clinical trial of a human acellular dermal matrix demonstrated superior healing rates for chronic diabetic foot ulcers over conventional care and an active acellular dermal matrix comparator. Wound Repair and Regeneration. 2017.
6. LifeNet Health, TR 0292, LifeNet Health's Decellularized Dermis, Dermacell, Comparison to the USP Monograph, Scaffold Human Dermis.
7. LifeNet Health, ED-22-038, Cytotoxicity Extraction Buffer Volume Comparison for Varying Thicknesses of Dermis.
8. LifeNet Health, TR ED-23-0306, In vivo Assessment of Local Tissue Response and Cell Infiltration – Animal study results may not be predictive of clinical results.
9. Moore MA, Samsell B, Wallis G, et al. Decellularization of human dermis using non-denaturing anionic detergent and endonuclease: a review. Cell Tissue Bank. 2015; 16(2):249-259. https://doi.org/10.1007/s10561-014-9467-4
10. LifeNet Health, TR-004-2020 Characterization of the Amnion, Chorion, and Trophoblast Layers of Decellularized and Freeze-Dried Placental Membrane. 2020.
11. LifeNet Health, PQ-19-307, Process Qualification: Placental Membrane for Wound
12. Matron Technical Monograph, 68-40-377.00
13. Capito AE, Tholpady SS, Agrawal H, Drake DB, Katz AJ. Evaluation of host tissue integration, revascularization, and cellular infiltration within various dermal substrates. Ann Plast Surg. 2012 May;68(5):495-500. doi: 10.1097/SAP.0b013e31823b6b01. PMID: 22531405
14. Cazzell S, Moyer PM, Samsell B, Dorsch K, McLean J, Moore MA. A Prospective, Multicenter, Single-Arm Clinical Trial for Treatment of Complex Diabetic Foot Ulcers with Deep Exposure Using Acellular Dermal Matrix. Adv Skin Wound Care. 2019 Sep;32(9):409-415
15. Kashimura T, Nagasaki K, Horigome M, Yoshida K, Soejima K. Selection of Artificial Dermis for Shortening Treatment Period: Integra versus Pelnac. Plast Reconstr Surg Glob Open. 2021 Jun 10;9(6):e3599. doi: 10.1097/GOX.0000000000003599. PMID: 34123683; PMCID: PMC8196999.
16. Matsuda K, Suzuki S, Ishiki N, Yoshioka K, Okada T, & Ikada Y. (1990). Influence of glycosaminoglycans on the collagen sponge component of a bilayer artificial skin. Biomaterials, 11(5), 351-355. https://doi.org/10.1016/0142-9612(90)90113-5
17. Title: An evaluation of an ultrasonic debridement system in patients with diabetic foot ulcers: a case series Publication title: Journal of Wound Care Author(s): Campitiello, Ferdinando, MD; Mancone, Manfredi, MD; Corte, Angela Della, MD; Guerniero, Raffaella, MD; Canonico, Silvestro Publisher: MA Healthcare Pub date: 4/2/2018 Volume: 27 Issue: 4 Pages: 222-228 Standard num: 09690700 EstdNum: 20522916 ISSN: 09690700 EISSN: 20522916 PMID: 29637829 DOI: 10.12968/jowc.2018.27.4.222
18. Kataoka Y, Kunimitsu M, Nakagami G, Koudounas S, Weller CD, Sanada H. Effectiveness of ultrasonic debridement on reduction of bacteria and biofilm in patients with chronic wounds: A scoping review. Int Wound J. 2021;18:176-186. https://doi.org/10.1111/iwj.13509
19. Campitiello F, Mancone M, Corte AD, Guerniero R, Canonico S. An evaluation of an ultrasonic debridement system in patients with diabetic foot ulcers: a case series. J Wound Care. 2018 Apr 2;27(4):222-228. doi: 10.12968/jowc.2018.27.4.222. PMID: 29637829
20. Murphy CA, Houghton P, Brandys T, Rose G, Bryant D. The effect of 22.5 kHz low-frequency contact ultrasound debridement (LFCUD) on lower extremity wound healing for a vascular surgery population: A randomised controlled trial. Int Wound J. 2018 Jun;15(3):460-472. doi: 10.1111/iwj.12887. Epub 2018 Jan 15. PMID: 29334176; PMCID: PMC7949649.
21. Paper title: Surgical debridement with SonicOne: an initial look at the bacterial load pre-and post-low frequency direct contact ultrasound Conference proceeding: 2016 WORLD UNION OF WOUND HEALING SOCIETIES CONGRESS, Florence, Italy, 9/25/2016 - 9/29/2016 Author(s): Abolghasemi, D., M. Baruch, and M. S. Granick Conference document type: Abstract Publisher: Wounds International Pub date: 9/2016